Adaptive Biotechnologies ADPT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.3%+1.0pp | 74.2%+2.4pp | 71.8%+5.8pp | 66%+3.5pp | 62.5%+2.8pp | |
| Operating margin | -15.8%+4.8pp | -20.6%+10.3pp | -30.9%+28.1pp | -59%+16.6pp | -75.7%+15.2pp | |
| Net margin | -16.8%+4.7pp | -21.5%+10.0pp | -31.5%+27.6pp | -59.1%+15.8pp | -74.8%+14.3pp | |
| Returns | ||||||
| Return on equity | -24.4%+3.8pp | -28.2%+9.0pp | -37.2%+20.4pp | -57.5%+3.4pp | -61%+1.4pp | |
| Return on invested capital | -13.2%+2.3pp | -15.5%+4.7pp | -20.2%+11.5pp | -31.8%+4.4pp | -36.2%+2.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.5×0.0× | 0.5×+0.1× | 0.4×0.0× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.4×0.0× | 3.3×0.0× | 3.4×+0.5× | 2.8×-0.1× | 2.9×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 1×0.0× | 1×-0.1× | 1×-0.2× | 1.2×+0.1× | 1.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $1.39-3.5% | $1.44+15.1% | $1.25+6.0% | $1.18-7.4% | $1.28-7.4% | |
| Valuation | ||||||
| Market capitalization | $2.14B-13.8% | $2.48B+8.8% | $2.28B+40.8% | $1.62B+46.6% | $1.1B+24.8% | |
| Price / sales | 7.2×-1.7× | 9×-0.1× | 9×+1.1× | 7.9×+2.1× | 5.8×+0.9× | |
| Price / book | 9.9×-1.5× | 11.3×+0.2× | 11.1×+2.1× | 9×+3.2× | 5.8×+1.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Adaptive Biotechnologies's profit margins?
- Adaptive Biotechnologies (ADPT) runs a 75.3% gross margin and a -15.8% operating margin, with a -16.8% net margin.
- Where do Adaptive Biotechnologies's ratios come from?
- Every ratio is computed from Adaptive Biotechnologies's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
